Tenecteplase in acute ischemic stroke: a new era in thrombolysis
Tenecteplase (TNK) is a genetically engineered variant of alteplase, showing promise for acute ischemic stroke treatment. With a longer half-life and higher fibrin specificity, TNK enables more targeted and efficient clot dissolution. Clinical trials demonstrate potential advantages, including impro...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações
2025-05-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1808088 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850246654074028032 |
|---|---|
| author | Gisele Sampaio Silva Eva Rocha Octávio Marques Pontes-Neto Sheila Ouriques Martins |
| author_facet | Gisele Sampaio Silva Eva Rocha Octávio Marques Pontes-Neto Sheila Ouriques Martins |
| author_sort | Gisele Sampaio Silva |
| collection | DOAJ |
| description | Tenecteplase (TNK) is a genetically engineered variant of alteplase, showing promise for acute ischemic stroke treatment. With a longer half-life and higher fibrin specificity, TNK enables more targeted and efficient clot dissolution. Clinical trials demonstrate potential advantages, including improved reperfusion rates and functional outcomes with lower systemic bleeding. Though not officially approved for this purpose by all regulatory agencies, TNK is used off-label and in acute stroke guidelines due to its ease of administration and effectiveness. The 0.25 mg/kg dosage within 4.5 hours of symptom onset was shown to be consistently effective and safe. Further trials are expected to identify patient subgroups that benefit most from TNK treatment. The present narrative review assesses the existing literature and evidence regarding the use of tenecteplase for the treatment of acute ischemic stroke. |
| format | Article |
| id | doaj-art-8b6b96b17d9d4db8ba7471d0c6d8a4d2 |
| institution | OA Journals |
| issn | 0004-282X 1678-4227 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Thieme Revinter Publicações |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj-art-8b6b96b17d9d4db8ba7471d0c6d8a4d22025-08-20T01:59:09ZengThieme Revinter PublicaçõesArquivos de Neuro-Psiquiatria0004-282X1678-42272025-05-01830500101110.1055/s-0045-1808088Tenecteplase in acute ischemic stroke: a new era in thrombolysisGisele Sampaio Silva0https://orcid.org/0000-0002-3247-3123Eva Rocha1https://orcid.org/0000-0002-0981-3919Octávio Marques Pontes-Neto2https://orcid.org/0000-0003-0317-843XSheila Ouriques Martins3https://orcid.org/0000-0002-8452-712XUniversidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil.Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil.Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Ribeirão Preto SP, Brazil.Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Departamento de Neurologia, Porto Alegre RS, Brazil.Tenecteplase (TNK) is a genetically engineered variant of alteplase, showing promise for acute ischemic stroke treatment. With a longer half-life and higher fibrin specificity, TNK enables more targeted and efficient clot dissolution. Clinical trials demonstrate potential advantages, including improved reperfusion rates and functional outcomes with lower systemic bleeding. Though not officially approved for this purpose by all regulatory agencies, TNK is used off-label and in acute stroke guidelines due to its ease of administration and effectiveness. The 0.25 mg/kg dosage within 4.5 hours of symptom onset was shown to be consistently effective and safe. Further trials are expected to identify patient subgroups that benefit most from TNK treatment. The present narrative review assesses the existing literature and evidence regarding the use of tenecteplase for the treatment of acute ischemic stroke.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1808088Ischemic StrokeThrombolytic TherapyTenecteplase |
| spellingShingle | Gisele Sampaio Silva Eva Rocha Octávio Marques Pontes-Neto Sheila Ouriques Martins Tenecteplase in acute ischemic stroke: a new era in thrombolysis Arquivos de Neuro-Psiquiatria Ischemic Stroke Thrombolytic Therapy Tenecteplase |
| title | Tenecteplase in acute ischemic stroke: a new era in thrombolysis |
| title_full | Tenecteplase in acute ischemic stroke: a new era in thrombolysis |
| title_fullStr | Tenecteplase in acute ischemic stroke: a new era in thrombolysis |
| title_full_unstemmed | Tenecteplase in acute ischemic stroke: a new era in thrombolysis |
| title_short | Tenecteplase in acute ischemic stroke: a new era in thrombolysis |
| title_sort | tenecteplase in acute ischemic stroke a new era in thrombolysis |
| topic | Ischemic Stroke Thrombolytic Therapy Tenecteplase |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0045-1808088 |
| work_keys_str_mv | AT giselesampaiosilva tenecteplaseinacuteischemicstrokeanewerainthrombolysis AT evarocha tenecteplaseinacuteischemicstrokeanewerainthrombolysis AT octaviomarquespontesneto tenecteplaseinacuteischemicstrokeanewerainthrombolysis AT sheilaouriquesmartins tenecteplaseinacuteischemicstrokeanewerainthrombolysis |